Immunocore Holdings plc (IMCR) Stock Forecast
IMCR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.23 / 5 from 13 analysts
- Price target
- $62.73 average of analyst targets
- Upside to target
- +113.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.10
- 52-week range
- $27.79 – $40.22
IMCR analyst ratings
13 analystsNumber of analysts at each rating.
IMCR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IMCR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.12 | −$0.26 | $0.02 | $0.00 | 0.0% | 12 |
| Current fiscal year (2026) | −$0.04 | −$0.46 | $0.29 | −$0.71 | +94.3% | 11 |
| Next fiscal year (2027) | −$0.75 | −$3.89 | $1.30 | −$0.07 | −970.1% | 12 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IMCR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $113.3M | $108.4M | $118.4M | +9.3% | 12 |
| Current fiscal year (2026) | $452.3M | $440.5M | $468.1M | +13.1% | 13 |
| Next fiscal year (2027) | $489.0M | $345.7M | $600.9M | +8.1% | 13 |
IMCR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IMCR revenue: reported and forecast
IMCR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.01 | $0.01 | −$0.12 | −$0.12 | −$0.12 | +810.3% | 1 up · 9 down |
| Current fiscal year (2026) | $0.14 | $0.17 | −$0.05 | −$0.05 | −$0.04 | −129.1% | 5 up · 6 down |
| Next fiscal year (2027) | −$0.62 | −$0.51 | −$0.75 | −$0.75 | −$0.75 | +20.7% | 2 up · 9 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IMCR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IMCR beat in 7 of 12.
What analysts expect from IMCR
13 analysts cover Immunocore; their consensus rating is buy (4.23 on a 1–5 scale, where 5 is a strong buy). The average price target is $62.73, 113.4% above the latest close of $29.40. Analysts expect earnings of −$0.04 per share for 2026, +94.3% from a year earlier. For 2027 the average estimate is −$0.75 per share on revenue of $489.0 million. Immunocore beat the EPS estimate in 7 of the last 12 quarters.
Related: IMCR income statement, IMCR key metrics, IMCR chart. See the IMCR stock overview for the latest quote and news.
IMCR forecast FAQ
What is Immunocore's price target?
The average analyst price target for Immunocore is $62.73, 113.4% above the latest close of $29.40.
Is Immunocore a buy, hold or sell?
Of 13 analysts covering Immunocore, 7 rate it a strong buy, 2 a buy, 4 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Immunocore's EPS forecast?
Analysts forecast −$0.04 per share for 2026 (range −$0.46 to $0.29); for 2027 the estimate is −$0.75.
What is Immunocore's revenue forecast?
The average revenue estimate for 2026 is $452.3 million, growth of 13.1%; for 2027 it is $489.0 million.
When does Immunocore report earnings?
Immunocore is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-0.10.
Does Immunocore usually beat earnings estimates?
Immunocore reported EPS at or above the analyst estimate in 7 of the last 12 quarters.